News

An enzyme called monoamine oxidase (MAO) may become a biomarker for the diagnosis and progression of Alzheimer’s disease, according to a new study. The study, “Close Correlation Of Monoamine Oxidase Activity With Progress Of Alzheimer’s Disease In Mice, Observed By In Vivo Two-Photon Imaging,” was published in the journal…

Treatment with the antibiotic Rocephin (ceftriaxone) may restore brain function in areas affected by Alzheimer’s disease, according to new research. The study, “Mapping Synaptic Glutamate Transporter Dysfunction In Vivo To Regions Surrounding Aβ Plaques By Iglusnfr Two-Photon Imaging,” was published in the journal Nature Communications. The hallmark of…

Two years of in-home occupational therapy, added to collaborative care, did not slow the rate of functional decline — the progressive loss of cognitive, emotional, and physical abilities — in patients with Alzheimer disease (AD), a new study reported. The study, “Targeting Functional Decline in Alzheimer Disease: A Randomized Trial,” was published…

In the wake of the failure of the investigational drug solanezumab, which stirred the debate over whether the prevailing amyloid theory of Alzheimer’s disease is still a viable working hypothesis, ProMIS Neurosciences announced their contribution to Alzheimer’s amyloid-related drug development. The announcement was accompanied by a commentary interpreting…

Women perform better than men on all memory measures but these sex differences tend to disappear as women age and enter menopause, according to a study published in the journal Menopause. These findings highlights the importance of ovarian hormones in maintaining memory function and could explain the reason why women are almost twice as likely as men to develop Alzheimer’s disease.